1. Home
  2. TLSA vs EDAP Comparison

TLSA vs EDAP Comparison

Compare TLSA & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.49

Market Cap

182.7M

Sector

Health Care

ML Signal

HOLD

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

HOLD

Current Price

$3.21

Market Cap

75.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLSA
EDAP
Founded
2013
1979
Country
United Kingdom
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.7M
75.5M
IPO Year
2000
1997

Fundamental Metrics

Financial Performance
Metric
TLSA
EDAP
Price
$1.49
$3.21
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$8.50
AVG Volume (30 Days)
414.9K
67.0K
Earning Date
01-01-0001
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$74,853,925.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.61
52 Week Low
$0.63
$1.21
52 Week High
$2.60
$3.45

Technical Indicators

Market Signals
Indicator
TLSA
EDAP
Relative Strength Index (RSI) 39.51 67.51
Support Level $1.45 $2.70
Resistance Level $1.62 $3.00
Average True Range (ATR) 0.16 0.33
MACD -0.01 0.04
Stochastic Oscillator 35.58 91.13

Price Performance

Historical Comparison
TLSA
EDAP

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: